SUSPECT ADVERSE REACTION REPORT

PA-TOLMAR, INC.-25PA058109

## I. REACTION INFORMATION

| 1. PATIENT INITIALS (first, last) | 1a. COUNTRY | 2. DATE OF BIRTH | | | 2a. AGE Years | 3. SEX | 4-6 REACTION ONSET | | |
|---|---|---|---|---|---|---|---|---|---|
| | | Day | Month | Year | | | Day | Month | Year |
| A-T | PANAMA | 30 | Dec | 1938 | 86 | Male | 20 | Mar | 2025 |

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58 (PSA increased (10037102), Prostatic specific antigen increased (10036975))
(20/Mar/2025 - ) - Not Recovered/Not Resolved/Ongoing

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

## II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (45 Milligram, Injection)(15276CUY; UNK; UNK)(45 Milligram, Injection)(Unknown)

Cont..

| 15. DAILY DOSE(S) | 16. ROUTE(S) OF ADMINISTRATION |
|---|---|
| 1) (45 milligram(s), 1 in 6 Month) | 1) Subcutaneous |
| 2) (45 milligram(s), 1 in 6 Month) | 2) Subcutaneous |

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

| 18. THERAPY DATE(S) (from/to) | 19. THERAPY DURATION |
|---|---|
| 1) (20/Mar/2025 - Ongoing) | |

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

| 24.REPORT NULLIFIED | 24b. MFR CONTROL NO. |
|---|---|
| ☐ YES ☐ NO | PA-TOLMAR, INC.-25PA058109 |
| 24c. DATE RECEIVED BY MANUFACTURER: 30/Jun/2025 | 24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL |
| DATE OF THIS REPORT: 08/Jul/2025 | 25a. REPORT TYPE: ☐ INITIAL ☑ FOLLOWUP |

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This Study report from PANAMA was received by Adium via a Patient Support Program (reference number: PA-ADIUM-PA-0026-20250325) on 25-MAR-2025 from a Consumer/Other Non-Health Prof regarding an Elderly 86 Years old Male patient who experienced elevated PSA (PSA increased), during Eligard (Leuprolide acetate) 45 milligrams therapy for Prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 26-MAR-2025.

The patient's medical history and current conditions included: Prostate cancer.

Concomitant medications were not reported.

On 31-OCT-2022, the patient began receiving Eligard 45 milligram, q 6 months via Subcutaneous use for Prostate cancer (Lot details and expiration dates were not provided). On 20-MAR-2025, unknown time after the dose of Eligard, the patient underwent prostatic specific antigen (PSA) tests, and the results were quite high compared to the results of 6 months ago (no values or reference ranges provided). Due to the PSA results, the doctor told him that the patient had to apply the Eligard scheduled dose of 20-MAR-2025; the same day he received the most recent dose of Eligard 45 milligram, q 6 months via Subcutaneous use for Prostate cancer (Lot number: 15276CUY; UNK; UNK; Expiration date: AUG-2026; UNK; UNK). Corrective treatment was not reported. Action taken with Eligard in response to the event was Dose Not Changed. De-challenge was Not applicable, and re-challenge was Not applicable.

Relevant test results included:

20-MAR-2025: Prostatic specific antigen: Increased - Unknown values (Ref range: Not provided).

The reporter did not assess the seriousness or causality of the event in relationship to Eligard.

On 30-Jun-2025, follow-up information was received by Adium via Patient Support Program “Asofarma a tu Lado” (reference number: PA-ADIUM-PA-0026-20250325 (V1)) from a consumer (non-healthcare professional) and sent to Tolmar on 01-Jul-2025. New information included: updated the clinical details of previous event (Prostatic specific antigen increased). Updated verbatim from "Elevated PSA" to "Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58". New lab data was added.

On an unknown date, in the last week the patient had his prostate antigen check-up tests, which he performs every 3 months, and the results were 9.58. The doctor advised that he should continue taking Eligard 45 mg every 6 months. No further details were provided.

Corrective treatment was not reported.

Relevant test results included:
On an unknown date: Prostatic specific antigen: 9.58 (Ref. range: Not provided).

Action taken with Eligard in response to the event was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of prostatic specific antigen increased was not resolved.

The reporter did not assess the seriousness of prostatic specific antigen increased.

The reporter assessed the causality of prostatic specific antigen increased in relationship to Eligard and Eligard unspecified device as related.

No further information is expected as consent to be contacted was not provided.

Listedness
prostatic specific antigen increased>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
prostatic specific antigen increased> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
prostatic specific antigen increased> Eligard®>listed as per USPI Eligard®>Feb-2025
prostatic specific antigen increased> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar):
This case is regarding an Elderly 86-year-old male patient who reported prostate specific antigen increased (PSA increased/last week he had his prostate antigen check-up tests that the results were 9.58), during Eligard (Leuprolide acetate) 45 milligrams therapy for Prostate cancer. Tolmar assessed the reported event as non-serious since it did not meet the ICH seriousness criteria. The causality of event prostate specific antigen increased was assessed a not related to Eligard(drug and device) as the event could be attributed to clinical nature of underlying prostate cancer which is known to progress despite treatment.

Additional Information (Continuation...)

Continuation Sheet for CIOMS report

Lab Result :

| Test Name | Test Date | Test Result | Normal Value |
|---|---|---|---|
| PSA TESTS | 20/Mar/2025 | | |
| PSA TESTS | | | |

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: PSA TESTS

Result Unstructured Data (free text) : Notes: Prostatic specific antigen increased (no values or reference ranges provided).

Test Date: 20/Mar/2025

2) Test Name: PSA TESTS

Result Unstructured Data (free text) : results were 9.58

Test Date:

Lab Comments :

1) Test Name : PSA TESTS

Lab Comments : Prostatic specific antigen increased (no values or reference ranges provided).

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form Strength : 1) 45 Milligram
2) 45 Milligram
Form of Admin : 1) Injection
2) Injection
Lot Number : 1) 15276CUY; UNK; UNK
2) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
(45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
2) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 20/Mar/2025 To :Continuing
2) From : 31/Oct/2022 To :Continuing
Action(s) Taken With Drug : Dose not changed

Causality

1) Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58 (PSA increased - 10037102, Prostatic specific antigen increased - 10036975 )
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58
CORE Labeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) 15276CUY; UNK; UNK
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Continuation Sheet for CIOMS report

Causality

1) Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58 (PSA increased - 10037102, Prostatic specific antigen increased - 10036975 )

| | |
|---|---|
| Causality as per reporter | : Related |
| Causality as per Mfr | : Not Related |
| DeChallenge | : Not applicable |
| ReChallenge | : Not Applicable |

Labeling :

1) Elevated PSA/last week he had his prostate antigen check-up tests that the results were 9.58
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) Expiration date: Aug-2026; UNK; UNK